Get Premium to unlock powerful stock data
Inovio Pharmaceuticals Inc logo

Inovio Pharmaceuticals Inc

$ 1.73 -0.04 (-2.26%) 04:00 PM EST
P/E:
At Loss
P/B:
1.10
Market Cap:
$ 396.24M
Enterprise V:
$ 78.66M
Volume:
5.19M
Avg Vol (2M):
5.74M
Also Trade In:
Volume:
5.19M
Market Cap $:
396.24M
PE Ratio:
At Loss
Avg Vol (2-Month):
5.74M
Enterprise Value $:
78.66M
PB Ratio:
1.10
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Inovio Pharmaceuticals Inc
NAICS : 325414 SIC : 2836
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Financials (Next Earnings Date:2022-08-09 Est.)

INO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:INO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.603
EPS (TTM) ($) -1.54
Beta 0.26
Volatility % 57.37
14-Day RSI 32.51
14-Day ATR ($) 0.24228
20-Day SMA ($) 2.3325
12-1 Month Momentum % -59.92
52-Week Range ($) 1.6 - 10.33
Shares Outstanding (Mil) 229.04

Piotroski F-Score Details

Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Inovio Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More